Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9966-9979

  Qi, Cuiling ^a   Zhou, Qin ^a   Li, Bin ^a   Yang, Yang ^a   Cao, Liu ^d   Ye, Yuxiang ^a   Li, Jiangchao ^a   Ding, Yi ^a   Wang, Huiping ^a   Wang, Jintao ^a   He, Xiaodong ^a   Zhang, Qianqian ^a   Lan, Tian ^a   Lee, Kenneth Ka Ho ^c   Li, Weidong ^a   Song, Xiaoyu ^d   Zhou, Jia ^e   Yang, Xuesong ^b   Wang, Lijing ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINA MEDICAL UNIVERSITY   (China)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Anticancer; Glipizide; Metastasis; Natriuretic peptide receptor A; Tumor angiogenesis

Indexed keywords

GLIMEPIRIDE; GLIPIZIDE; NATRIURETIC PEPTIDE RECEPTOR A; ANGIOGENESIS INHIBITOR; ANTIDIABETIC AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; LUNG METASTASIS; MELANOMA; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; ANIMAL; BREAST NEOPLASMS; CHICK EMBRYO; CHORIOALLANTOIS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMALE; HEK293 CELL LINE; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF 7 CELL LINE; METASTASIS; MOUSE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DISEASE MODELS, ANIMAL; FEMALE; GLIPIZIDE; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOGLYCEMIC AGENTS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924946354     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2483     Document Type: Article

References (39)

1. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer. 1984;49:405-13.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-64.
3. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
4. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol. 1996;40:1189-97.
5. Tufan AC, Satrioglutufan NL. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of antiangiogenic agents. Curr Cancer Drug Tar. 2005;5:249-66.
6. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA. Type 2 diabetes and oral antihyperglycemic drugs. Current medicinal chemistry. 2008;15:61-74.
7. Riddle MC. Oral pharmacologic management of type 2 diabetes. American family physician. 1999;60:2613-20.
8. Skyler JS. Diabetes mellitus: pathogenesis and treatment strategies. Journal of medicinal chemistry. 2004;47:4113-7.
9. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161:147-52.
10. Seow A, Yuan JM, Koh WP, Lee HP, Yu MC. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. Journal of the National Cancer Institute. 2006;98:135-8.
11. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British journal of cancer. 2005;92:2076-83.
12. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Archives of internal medicine. 2006;166:1871-7.
13. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. International journal of cancer. 2006;118:2105-9.
14. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533-9.
15. Yang X, Shang H, Katz A, Li X. A modified aggregate culture for chondrogenesis of human adipose-derived stem cells genetically modified with growth and differentiation factor 5. Biores Open Access. 2013;2:258-65.
16. Bliss DP, Jr., Battey JF, Linnoila RI, Birrer MJ, Gazdar AF, Johnson BE. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. Journal of the National Cancer Institute. 1990;82:305-10.
17. Wang X, Raulji P, Mohapatra SS, Patel R, Hellermann G, Kong X, Vera PL, Meyer-Siegler KL, Coppola D, Mohapatra S. Natriuretic peptide receptor a as a novel target for prostate cancer. Molecular cancer. 2011;10:10-56.
18. Kong X, Wang X, Xu W, Behera S, Hellermann G, Kumar A, Lockey RF, Mohapatra S, Mohapatra SS. Natriuretic peptide receptor a as a novel anticancer target. Cancer research. 2008;68:249-56.
19. Mallela J, Ravi S, Jean Louis F, Mulaney B, Cheung M, Sree Garapati U, Chinnasamy V, Wang C, Nagaraj S, Mohapatra SS, Mohapatra S. Natriuretic Peptide receptor a signaling regulates stem cell recruitment and angiogenesis: a model to study linkage between inflammation and tumorigenesis. Stem cells. 2013;31:1321-9.
20. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Molecular and cellular biology. 1992;12:954-61.
21. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest. 2005;115:1666-74.
22. McKay MK, Huxley VH. ANP increases capillary permeability to protein independent of perfusate protein composition. Am J Physiol. 1995;268:1139-48.
23. Nakayama S, Uto Y, Tanimoto K, Okuno Y, Sasaki Y, Nagasawa H, Nakata E, Arai K, Momose K, Fujita T, Hashimoto T, Okamoto Y, Asakawa Y, et al. TX-2152: a conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity. Bioorg Med Chem. 2008;16:7705-14.
24. Moiseeva O, Deschênes-Simard X, Pollak M, Ferbeyre G. Metformin, aging and cancer. Aging (Albany NY). 2013;5:330-1.
25. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011;2:222-33.
26. Cioce M, Valerio MC, Casadei L, Pulito C, Sacconi A, Mori F, Biagioni F, Manetti C, Muti P, Strano S, Blandino G. Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget. 2014;5:4129-43.
27. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B, Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012;3:395-8.
28. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care. 2006;29:1990-1.
29. Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, Marchionni N, Mannucci E. Are sulphonylureas all the same? A cohort study on cardiovascular and cancerrelated mortality. Diabetes Metab Res Rev. 2007;23:479-84.
30. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009;46:279-84.
31. Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP, Ng VW, Luk AO, Ozaki R, Tong PC, Chow CC, Chan JC. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010;90:343-51.
32. Simonson DC1, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebocontrolled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care. 1997;20:597-606.
33. Menendez JA, Quirantes-Piné R, Rodríguez-Gallego E, Cufí S, Corominas-Faja B, Cuyàs E, Bosch-Barrera J, Martin-Castillo B, Segura-Carretero A, Joven J. Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget. 2014;5:2344-8.
34. Blagosklonny MV. A new science-business paradigm in anticancer drug development. Trends Biotechnol. 2003;21:103-6.
35. Siamblis D, Karnabatidis D, Hatjikondi O, Kalogeropoulou C, Kardamakis D, Dimopoulos J. A novel radiological approach for the experimental study of angiogenesis: angiography of the chick embryo and its chorioallantoic membrane. European journal of radiology. 1996;21:220-4.
36. Folkman J. Tumor angiogenesis: therapeutic implications. The New England journal of medicine. 1971 18;285:1182-6.
37. Chan T, Burggren W. Hypoxic incubation creates differential morphological effects during specific developmental critical windows in the embryo of the chicken (Gallus gallus). Respir Physiol Neurobiol. 2005;145:251-63.
38. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A, Bikfalvi A. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA. 2005;102:1643-8.
39. Ozdemir BH, Akcali Z, Haberal M. Hypercholesterolemia impairs angiogenesis in patients with breast carcinoma and, therefore, lowers the risk of metastases. Am J Clin Pathol. 2004;122:696-703.